Skip to main content
Erschienen in: Intensive Care Medicine 12/2016

23.07.2016 | Systematic Review

Control groups in recent septic shock trials: a systematic review

verfasst von: Ville Pettilä, Peter Buhl Hjortrup, Stephan M. Jakob, Erika Wilkman, Anders Perner, Jukka Takala

Erschienen in: Intensive Care Medicine | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The interpretation of septic shock trial data is profoundly affected by patients, control intervention, co-interventions and selected outcome measures. We evaluated the reporting of control groups in recent septic shock trials.

Methods

We searched for original articles presenting randomized clinical trials (RCTs) in adult septic shock patients from 2006 to 2016. We included RCTs focusing on septic shock patients with at least two parallel groups and at least 50 patients in the control group. We selected and evaluated data items regarding patients, control group characteristics, and mortality outcomes, and calculated a data completeness score to provide an overall view of quality of reporting.

Results

A total of 24 RCTs were included (mean n = 287 patients and 71 % of eligible patients were randomized). Of the 24 studies, 14 (58 %) presented baseline data on vasopressors and 58 % the proportion of patients with elevated lactate values. Five studies (21 %) provided data to estimate the proportion of septic shock patients fulfilling the Sepsis-3 definition. The mean data completeness score was 19 out of 36 (range 8–32). Of 18 predefined control group characteristics, a mean of 8 (range 2–17) were reported. Only 2 (8 %) trials provided adequate data to confirm that their control group treatment represented usual care.

Conclusions

Recent trials in septic shock provide inadequate data on the control group treatment and hemodynamic values. We propose a standardized trial dataset to be created and validated, comprising characteristics of patient population, interventions administered, hemodynamic values achieved, surrogate organ dysfunction, and mortality outcomes, to allow better analysis and interpretation of future trial results.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Shankar-Hari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:775–787CrossRefPubMedPubMedCentral Shankar-Hari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:775–787CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Deans KJ, Minneci PC, Suffredini AF et al (2007) Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med 35:1509–1516CrossRefPubMed Deans KJ, Minneci PC, Suffredini AF et al (2007) Randomization in clinical trials of titrated therapies: unintended consequences of using fixed treatment protocols. Crit Care Med 35:1509–1516CrossRefPubMed
3.
Zurück zum Zitat Takala J (2009) Better conduct of clinical trials: the control group in critical care trials. Crit Care Med 37(1 Suppl):S80–S90CrossRefPubMed Takala J (2009) Better conduct of clinical trials: the control group in critical care trials. Crit Care Med 37(1 Suppl):S80–S90CrossRefPubMed
4.
Zurück zum Zitat Investigators PROCESS, Yealy DM, Kellum JA et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693CrossRef Investigators PROCESS, Yealy DM, Kellum JA et al (2014) A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:1683–1693CrossRef
5.
Zurück zum Zitat ARISE Investigators, ANZICS Clinical Trials Group, Peake S et al (2014) Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371:1496–1506CrossRef ARISE Investigators, ANZICS Clinical Trials Group, Peake S et al (2014) Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371:1496–1506CrossRef
6.
Zurück zum Zitat Mouncey PR, Osborn T, Power GS, Trial Investigators PROMISE et al (2015) Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372:1301–1311CrossRefPubMed Mouncey PR, Osborn T, Power GS, Trial Investigators PROMISE et al (2015) Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372:1301–1311CrossRefPubMed
7.
Zurück zum Zitat Caironi P, Tognoni G, Masson S, Albios Study Investigators et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421CrossRefPubMed Caironi P, Tognoni G, Masson S, Albios Study Investigators et al (2014) Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370:1412–1421CrossRefPubMed
8.
Zurück zum Zitat De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789CrossRefPubMed De Backer D, Biston P, Devriendt J et al (2010) Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779–789CrossRefPubMed
9.
Zurück zum Zitat Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with moxifloxacin and meropenem vs. meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307:2390–2399CrossRefPubMed Brunkhorst FM, Oppert M, Marx G et al (2012) Effect of empirical treatment with moxifloxacin and meropenem vs. meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 307:2390–2399CrossRefPubMed
10.
Zurück zum Zitat Vincent JL, Marshall JC, Dellinger RP et al (2015) Talactoferrin in severe sepsis: results from the phase II/III Oral tAlactoferrin in Severe sepsIS Trial. Crit Care Med 43:1832–1838CrossRefPubMed Vincent JL, Marshall JC, Dellinger RP et al (2015) Talactoferrin in severe sepsis: results from the phase II/III Oral tAlactoferrin in Severe sepsIS Trial. Crit Care Med 43:1832–1838CrossRefPubMed
11.
Zurück zum Zitat Lin SM, Huang CD, Lin HC, Liu CY, Wang CH, Kuo HP (2006) A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 26:551–557CrossRefPubMed Lin SM, Huang CD, Lin HC, Liu CY, Wang CH, Kuo HP (2006) A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. Shock 26:551–557CrossRefPubMed
12.
Zurück zum Zitat Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684CrossRefPubMed Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 370:676–684CrossRefPubMed
13.
Zurück zum Zitat Werdan K, Pilz G, Bujdoso O et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693–2701CrossRefPubMed Werdan K, Pilz G, Bujdoso O et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693–2701CrossRefPubMed
14.
Zurück zum Zitat Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124CrossRefPubMed Sprung CL, Annane D, Keh D et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124CrossRefPubMed
15.
Zurück zum Zitat Stephens DP, Thomas JH, Higgins A et al (2008) Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 36:448–454CrossRefPubMed Stephens DP, Thomas JH, Higgins A et al (2008) Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock. Crit Care Med 36:448–454CrossRefPubMed
16.
Zurück zum Zitat Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887CrossRefPubMed Russell JA, Walley KR, Singer J et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358:877–887CrossRefPubMed
17.
Zurück zum Zitat Dhainaut JF, Antonelli M, Wright P et al (2009) Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med 35:1187–1195CrossRefPubMed Dhainaut JF, Antonelli M, Wright P et al (2009) Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock. Intensive Care Med 35:1187–1195CrossRefPubMed
18.
Zurück zum Zitat Palizas F, Dubin A, Regueira T et al (2009) Gastric tonometry versus cardiac index as resuscitation goals in septic shock: a multicenter, randomized, controlled trial. Crit Care 13:R44CrossRefPubMedPubMedCentral Palizas F, Dubin A, Regueira T et al (2009) Gastric tonometry versus cardiac index as resuscitation goals in septic shock: a multicenter, randomized, controlled trial. Crit Care 13:R44CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA (2010) Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 303:739–746CrossRefPubMedPubMedCentral Jones AE, Shapiro NI, Trzeciak S, Arnold RC, Claremont HA, Kline JA (2010) Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 303:739–746CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Patel GP, Grahe JS, Sperry M et al (2010) Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 33:375–380CrossRefPubMed Patel GP, Grahe JS, Sperry M et al (2010) Efficacy and safety of dopamine versus norepinephrine in the management of septic shock. Shock 33:375–380CrossRefPubMed
21.
Zurück zum Zitat Annane D, Cariou A, Maxime V et al (2010) Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 303:341–348CrossRefPubMed Annane D, Cariou A, Maxime V et al (2010) Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA 303:341–348CrossRefPubMed
22.
Zurück zum Zitat Huh JW, Choi HS, Lim CM et al (2011) Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3 days with 7 days. Respirology 16:1088–1095CrossRefPubMed Huh JW, Choi HS, Lim CM et al (2011) Low-dose hydrocortisone treatment for patients with septic shock: a pilot study comparing 3 days with 7 days. Respirology 16:1088–1095CrossRefPubMed
23.
Zurück zum Zitat Ranieri VM, Thompson BT, Barie BS, PROWESS-SHOCK study group et al (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055–2064CrossRefPubMed Ranieri VM, Thompson BT, Barie BS, PROWESS-SHOCK study group et al (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055–2064CrossRefPubMed
24.
Zurück zum Zitat Perner A, Haase N, Guttormsen AB, Scandinavian Critical Care Trials Group (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134CrossRefPubMed Perner A, Haase N, Guttormsen AB, Scandinavian Critical Care Trials Group (2012) Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med 367:124–134CrossRefPubMed
25.
Zurück zum Zitat Schortgen F, Clabault K, Katsahian S et al (2012) Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 185:1088–1095CrossRefPubMed Schortgen F, Clabault K, Katsahian S et al (2012) Fever control using external cooling in septic shock: a randomized controlled trial. Am J Respir Crit Care Med 185:1088–1095CrossRefPubMed
26.
Zurück zum Zitat Annane D, Timsit JF, Megarbane B et al (2013) Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med 187:1091–1097CrossRefPubMed Annane D, Timsit JF, Megarbane B et al (2013) Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med 187:1091–1097CrossRefPubMed
27.
Zurück zum Zitat Joannes-Boyau O, Honore PM, Perez P et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535–1546CrossRefPubMed Joannes-Boyau O, Honore PM, Perez P et al (2013) High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 39:1535–1546CrossRefPubMed
28.
Zurück zum Zitat Holst LB, Haase N, Wetterslev J, TRISS trial group, Scandinavian Critical Care Trials Group et al (2014) Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 371:1381–1391CrossRefPubMed Holst LB, Haase N, Wetterslev J, TRISS trial group, Scandinavian Critical Care Trials Group et al (2014) Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 371:1381–1391CrossRefPubMed
29.
Zurück zum Zitat Asfar P, Meziani F, Hamel JF, Investigators Sepsispam et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583–1593CrossRefPubMed Asfar P, Meziani F, Hamel JF, Investigators Sepsispam et al (2014) High versus low blood-pressure target in patients with septic shock. N Engl J Med 370:1583–1593CrossRefPubMed
30.
Zurück zum Zitat Lu NF, Zheng RQ, Lin H, Shao J, Yu JQ, Yang DG (2015) Improved sepsis bundles in the treatment of septic shock: a prospective clinical study. Am J Emerg Med 33:1045–1049CrossRefPubMed Lu NF, Zheng RQ, Lin H, Shao J, Yu JQ, Yang DG (2015) Improved sepsis bundles in the treatment of septic shock: a prospective clinical study. Am J Emerg Med 33:1045–1049CrossRefPubMed
31.
Zurück zum Zitat Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975–984CrossRefPubMedPubMedCentral Payen DM, Guilhot J, Launey Y et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975–984CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810CrossRefPubMedPubMedCentral Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315:801–810CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Kavanagh BP, Nurok M (2015) Standardized intensive care—protocol misalignment and impact misattribution. Am J Respir Crit Care Med 193:17–22CrossRef Kavanagh BP, Nurok M (2015) Standardized intensive care—protocol misalignment and impact misattribution. Am J Respir Crit Care Med 193:17–22CrossRef
34.
Zurück zum Zitat Porter ME, Larsson S, Lee TH (2016) Standardizing patient outcomes measurement. N Engl J Med 374:504–506CrossRefPubMed Porter ME, Larsson S, Lee TH (2016) Standardizing patient outcomes measurement. N Engl J Med 374:504–506CrossRefPubMed
35.
Zurück zum Zitat Myles PS, Grocott MP, Boney O, Moonesinghe SR, COMPAC-StEP Group (2016) Standardizing end points in perioperative trials: towards a core and extended outcome set. Br J Anaesth 116:586–589CrossRefPubMed Myles PS, Grocott MP, Boney O, Moonesinghe SR, COMPAC-StEP Group (2016) Standardizing end points in perioperative trials: towards a core and extended outcome set. Br J Anaesth 116:586–589CrossRefPubMed
36.
Zurück zum Zitat Schulz KF, Altman DG, Moher D, For the CONSORT group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. J Clin Epidem 63:834–840CrossRef Schulz KF, Altman DG, Moher D, For the CONSORT group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. J Clin Epidem 63:834–840CrossRef
37.
Zurück zum Zitat Annane D (2009) Improving clinical trials in the critically ill: unique challenge—sepsis. Crit Care Med 37:S117–S128CrossRefPubMed Annane D (2009) Improving clinical trials in the critically ill: unique challenge—sepsis. Crit Care Med 37:S117–S128CrossRefPubMed
Metadaten
Titel
Control groups in recent septic shock trials: a systematic review
verfasst von
Ville Pettilä
Peter Buhl Hjortrup
Stephan M. Jakob
Erika Wilkman
Anders Perner
Jukka Takala
Publikationsdatum
23.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Intensive Care Medicine / Ausgabe 12/2016
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-016-4444-y

Weitere Artikel der Ausgabe 12/2016

Intensive Care Medicine 12/2016 Zur Ausgabe

Imaging in Intensive Care Medicine

Ultrasonographic diagnosis of tracheal compression

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 Leitsymptom Rückenschmerzen Nachrichten

Personen mit chronischen Rückenschmerzen, die von einfühlsamen Ärzten und Ärztinnen betreut werden, berichten über weniger Beschwerden und eine bessere Lebensqualität.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.